CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of innovative oncology therapeutics. The company's core strategy revolves around its proprietary conditional activation platform technology, designed to create biologics that are selectively activated within the tumor microenvironment. This approach aims to enhance therapeutic efficacy while minimizing off-target toxicities, thereby widening the therapeutic window for a range of cancer treatments. CytomX leverages this platform to advance its pipeline, which includes conditionally activated antibody-drug conjugates (ADCs) and T-cell engaging bispecific antibodies. Key pipeline candidates include CX-904, a bispecific antibody targeting EGFR on tumor cells and CD3 on T cells; CX-2051, a conditionally activated ADC for EpCAM-expressing cancers; and CX-801, a PROBODY cytokine. The company is also developing CX-2029, a conditional ADC targeting CD71, and has a PROBODY version of ipilimumab in its pipeline. CytomX has established significant strategic collaborations with leading pharmaceutical companies such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, underscoring the broad applicability and potential of its technology. Furthermore, a clinical trial collaboration with Merck is evaluating CX-801 in combination with KEYTRUDA. This focus on targeted activation and strategic partnerships positions CytomX to address significant unmet needs in cancer therapy.